vimarsana.com
Home
Live Updates
F. Hoffmann-La Roche Ltd: FDA grants Breakthrough Therapy Designation to Roches inavolisib for advanced hormone receptor-positive, HER2-negative breast cancer with a PIK3CA mutation : comparemela.com
F. Hoffmann-La Roche Ltd: FDA grants Breakthrough Therapy Designation to Roche's inavolisib for advanced hormone receptor-positive, HER2-negative breast cancer with a PIK3CA mutation
The designation is based on Phase III INAVO120 results, showing the inavolisib-based regimen more than doubled progression-free survival compared with palbociclib and fulvestrant alone in the first-line
Related Keywords
United States ,
San Antonio ,
Texas ,
Switzerland ,
Japan ,
America ,
Sileia Urech ,
Simon Goldsborough ,
Nathalie Altermatt ,
Bruno Eschli ,
Levi Garraway ,
Rebekka Schnell ,
Kirti Pandey ,
Birgit Masjost ,
Loren Kalm ,
Sabine Borngr ,
Karsten Kleine ,
Yvette Petillon ,
Drug Administration ,
Head Of Global Product Development ,
Roche Group ,
European Medicines Agency ,
Genentech ,
Breakthrough Therapy Designation ,
Chief Medical Officer ,
Global Product ,
Therapy Designation ,
European Medicines ,
Dow Jones Sustainability Indices ,
Chugai Pharmaceutical ,
San Antonio Breast Cancer Symposium ,
Systematic Review ,
Diagnostic Workup ,
Intj Breast ,
Breakthrough Therapy Approvals ,
Breakthrough Therapy ,
Study Evaluating ,
Patients With ,
Hormone Receptor Positive ,
Locally Advanced ,
Metastatic Breast ,
Combination With Phesgo Versus Placebo ,
Combination With Phesgo ,
Participants With ,
Positive Locally Advanced ,
Metastatic Breast Cancer ,
Williston Park ,
Adv Med ,
Ihr Portfolio ,
comparemela.com © 2020. All Rights Reserved.